Stock Track | HBM HOLDINGS-B Soars 5.28% Intraday on Strong 2025 Financial Results with Revenue Tripling and Profit Surging 33-Fold

Stock Track03-31

HBM HOLDINGS-B's stock soared 5.28% during intraday trading on Tuesday, following the release of its exceptional full-year 2025 financial results.

The biopharmaceutical company reported that its total revenue reached approximately US$158 million, representing a staggering 314.6% increase year-over-year. Net profit for the year surged to approximately US$92 million, a remarkable 33-fold increase compared to 2024. This explosive growth was primarily driven by long-term strategic collaborations with multinational pharmaceutical companies, global licensing agreements, and the robust performance of its Nona Biosciences unit.

Strategic partnerships formed in 2025, including deals with AstraZeneca, Bristol Myers Squibb, Otsuka, and Pfizer, have created a high-value global innovation ecosystem. The company also maintains a strong cash position of approximately US$403 million and is advancing a diversified pipeline of nearly 20 drug candidates across immunology and oncology, positioning it for sustainable long-term growth.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1172631863?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-31 09:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1172631863","market":"hk","top_or_hot":-1,"title":"Stock Track | HBM HOLDINGS-B Soars 5.28% Intraday on Strong 2025 Financial Results with Revenue Tripling and Profit Surging 33-Fold","media":"Stock Track","content":"<p>HBM HOLDINGS-B's stock soared 5.28% during intraday trading on Tuesday, following the release of its exceptional full-year 2025 financial results.</p><p>The biopharmaceutical company reported that its total revenue reached approximately US$158 million, representing a staggering 314.6% increase year-over-year. Net profit for the year surged to approximately US$92 million, a remarkable 33-fold increase compared to 2024. This explosive growth was primarily driven by long-term strategic collaborations with multinational pharmaceutical companies, global licensing agreements, and the robust performance of its Nona Biosciences unit.</p><p>Strategic partnerships formed in 2025, including deals with AstraZeneca, Bristol Myers Squibb, Otsuka, and Pfizer, have created a high-value global innovation ecosystem. The company also maintains a strong cash position of approximately US$403 million and is advancing a diversified pipeline of nearly 20 drug candidates across immunology and oncology, positioning it for sustainable long-term growth.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | HBM HOLDINGS-B Soars 5.28% Intraday on Strong 2025 Financial Results with Revenue Tripling and Profit Surging 33-Fold</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | HBM HOLDINGS-B Soars 5.28% Intraday on Strong 2025 Financial Results with Revenue Tripling and Profit Surging 33-Fold\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-03-31 09:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>HBM HOLDINGS-B's stock soared 5.28% during intraday trading on Tuesday, following the release of its exceptional full-year 2025 financial results.</p><p>The biopharmaceutical company reported that its total revenue reached approximately US$158 million, representing a staggering 314.6% increase year-over-year. Net profit for the year surged to approximately US$92 million, a remarkable 33-fold increase compared to 2024. This explosive growth was primarily driven by long-term strategic collaborations with multinational pharmaceutical companies, global licensing agreements, and the robust performance of its Nona Biosciences unit.</p><p>Strategic partnerships formed in 2025, including deals with AstraZeneca, Bristol Myers Squibb, Otsuka, and Pfizer, have created a high-value global innovation ecosystem. The company also maintains a strong cash position of approximately US$403 million and is advancing a diversified pipeline of nearly 20 drug candidates across immunology and oncology, positioning it for sustainable long-term growth.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02142","symbol_name":"和铂医药-B","start_time":0,"source_url":"","article_id":"1172631863","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1172631863","pubTimestamp":1774922109,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"HBM HOLDINGS-B's stock soared 5.28% during intraday trading on Tuesday, following the release of its exceptional full-year 2025 financial results.The biopharmaceutical company reported that its total...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02142":"和铂医药-B"},"translate_title":"个股轨迹|HBM HOLDINGS-B盘中大涨5.28%，2025年财报强劲，营收增长3倍，利润飙升33倍","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02142":1},"content_text":"HBM HOLDINGS-B's stock soared 5.28% during intraday trading on Tuesday, following the release of its exceptional full-year 2025 financial results.The biopharmaceutical company reported that its total revenue reached approximately US$158 million, representing a staggering 314.6% increase year-over-year. Net profit for the year surged to approximately US$92 million, a remarkable 33-fold increase compared to 2024. This explosive growth was primarily driven by long-term strategic collaborations with multinational pharmaceutical companies, global licensing agreements, and the robust performance of its Nona Biosciences unit.Strategic partnerships formed in 2025, including deals with AstraZeneca, Bristol Myers Squibb, Otsuka, and Pfizer, have created a high-value global innovation ecosystem. The company also maintains a strong cash position of approximately US$403 million and is advancing a diversified pipeline of nearly 20 drug candidates across immunology and oncology, positioning it for sustainable long-term growth.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1172631863","isCrawlerRequest":true}